AR and prostate cancer: Here, using a cohort of well characterised prostate cancer cell lines with known and experimentally validated AR-V7 expression, we thoroughly tested the seven commercially available AR-V7 antibodies for their ability to truly detect AR-V7 by immunoblotting and immunocytostaining.